SCHEMBL5832201

SCHEMBL5832201

N#CCc1ccc(-c2nc3ccccc3o2)cc1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 8/20 0.47
KDM4E B2RXH2 5/20 0.47
ALDH1A1 P00352 5/20 0.47
HPGD P15428 5/20 0.47
SMN1; SMN2 Q16637 5/20 0.47
TP53 P04637 4/20 0.47
HSD17B10 Q99714 2/20 0.47
RAB9A P51151 6/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
ATM Q13315 1/20 0.47
NFKB1 P19838 2/20 0.44
STAT1 P42224 2/20 0.44
NFKB2 Q00653 2/20 0.44
RELA Q04206 2/20 0.44
HCRTR1 O43613 2/20 0.44
MAPT P10636 2/20 0.44
LMNA P02545 1/20 0.44
GAA P10253 1/20 0.44
GFER P55789 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5832068 0.87 ESR2 (0.49) NPC1KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL5832504 0.85 NPC1 (0.54) NPC1KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL5832027 0.85 NPC1 (0.47) NPC1KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL2493176 0.85 PTGS2 (0.52) NPC1KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL5831686 0.85 NPC1 (0.52) NPC1KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL5831898 0.84 NPC1 (0.52) NPC1KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL5831901 0.84 HSPD1 (0.46) NPC1KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL5832573 0.84 SMN1; SMN2 (0.52) NPC1KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL5831884 0.84 KDM4E (0.57) NPC1KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL11696502 0.83 NPC1 (0.50) NPC1KDM4EALDH1A1HPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7087601-B2 Metabotropic glutamate receptor-5 modulators MERCK & CO., INC. (US) 2006-08-08 US disclosed
EP-1453815-A4 METABOTROPIC GLUTAMATE RECEPTOR-5 MODULATORS MERCK & CO INC (US) 2005-04-06 EP disclosed
US-20050065340-A1 Metabotropic glutamate receptor-5 modulators MERCK SHARP & DOHME CORP. 2005-03-24 US disclosed
EP-1453815-A1 METABOTROPIC GLUTAMATE RECEPTOR-5 MODULATORS Merck & Co., Inc. (US) 2004-09-08 EP disclosed
WO-2004030637-A2 TREATMENT OF OBESITY AND OTHER DISORDERS ASSOCIATED WITH EXCESSIVE FOOD INTAKE MERCK & CO., INC. (US) 2004-04-15 WO disclosed
WO-2003048137-A1 METABOTROPIC GLUTAMATE RECEPTOR-5 MODULATORS MERCK & CO., INC. (US) 2003-06-12 WO disclosed
US-4046905-A Anti-inflammatory, analgesic and antipyretic phenylacetic acids MERCK & CO., INC. (US) 1977-09-06 US disclosed
US-3947582-A Phenylacetic acid compounds in treating abnormal platelet aggregation MERCK & CO., INC. (US) 1976-03-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050065340-A1 Metabotropic glutamate receptor-5 modulators GRM5, GRIK5, GRM1 NPC1 3080/4885KDM4E 1754/4885ALDH1A1 2908/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.